tbuckley/cabot-search huggingface dataset:
Suicide and Attempted Suicide in the United States During the 21st Century
Authors: Eric D. Caine
Journal: JAMA Psychiatry (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
A novel method to identify and monitor endogenous tumor-reactive T cells by high expression of CD11a (LFA-1) and PD-1 (CD279) as immunologic readout for evaluating the efficacy of PD-1 blockade.
Authors: Haidong Dong, Svetomir Markovic, Christopher J Krco, Eugene D. Kwon
Journal: Journal of Clinical Oncology (2013)

3037 Background: Tumor immunotherapies directed towards enhancing natural or endogenous anti-tumor T-cell immunity in patients with advanced malignancies are currently being implemented in clinic with promising results. In order to optimize therapeutic protocols and monitor the effectiveness of such therapies, a reliable T-cell marker is needed. Methods: We utilized CD11a (LFA-1, lymphocyte functional-associated antigen 1), an integrin up-regulated on effector and memory CD8 T-cells, and PD-1 (programmed death-1), an immunoregulatory receptor expressed by activated T cells, as biomarkers to identify, quantitate and monitor endogenous tumor-reactive cytotoxic lymphocytes (CTLs) in two mouse tumor models and the peripheral blood (PB) of 12 patients with stage IV melanoma. Results: High expression of CD11a and PD-1 was identified among CD8 T-cells residing within primary and metastatic murine tumor sites, as well as in spontaneous murine breast cancer tissues. In the PB of melanoma patients, tumor antigen-specific CD8 T cells were associated with a population of CD11a high CD8 T-cells which co-expressed high levels of PD-1, as opposed to eleven healthy donors who had a much lower frequency of PD-1+ CD11a high CD8 T-cells (p &lt;0.0001). Phenotypic analysis showed that CD11a high CD8 T-cells are proliferating (Ki67 positive) activated (CD62L low, CD69 high) T-cells. Increased CD11a high CD8 T-cells and delayed tumor growth were observed in PD-1 deficient mice, suggesting that the antitumor effector function of CD8 T cells is compromised by co-expression of elevated levels of PD-1. Conclusions: CD11a high CD8 T-cell population expresses high levels of PD-1 and is likely the cellular target of PD-1 blockade therapy. High expression of CD11a (LFA-1) and PD-1 (CD279) by CD8 T-cells may represent a novel biomarker to identify and monitor endogenous tumor-reactive CTLs. This may not only provide an immunological readout for evaluating the efficacy of therapy, but also contribute to the selection of patients with solid malignancies likely to benefit from anti-PD-1 therapy.
AB0329 A Study on Characteristics of Rheumatoid Arthritis Patients Achieving HAQ Remission with 6 Months of Biologic Treatment
Authors: Y. Miwa, R. Takahashi, N. Yajima, K. Wakabayashi, T. Tokunaga, S. Ishii, A. Nishimi, T. Kasama, K. Oh, Y. Toyoshima, K. Inagaki
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Biologic agents are highly effective for rheumatoid arthritis (RA); however, not all cases achieve HAQ remission. Although previous studies have reported the prognostic factors, there is no report on predictive factors for HAQ remission. <h3>Objectives</h3> To study predictive factors for HAQ remission, which is one of the treatment goals in RA, after using biologic agents for 6 months. <h3>Methods</h3> The subjects were 333 RA patients treated with biologic agents for 6 months. The following patient9s characteristics were investigated: age, gender, the number of previous drugs, disease duration, the type of biologic agents, baseline steroid dosage, MTX dosage, serum RF, MMP-3, ACPA, TNF-α, and IL-6. For evaluation we used SDAI for RA disease activity, HAQ for ADL, Short Form (SF)-36 for QOL, and Hamilton Depression Rating Scale (HAM-D) or Self-rating depression scale (SDS) for depression status. HAQ remission was defined by HAQ0.5 after 6 months of treatment. The subjects were divided into two groups: patients with HAQ0.5 and patients with HAQ &gt;0.5 at 6 months, and a retrospective study was conducted. 101 patients were excluded from the study due to loss to 6-month follow-up, and a total of 232 patients were analyzed. <h3>Results</h3> Compared with a group of RA patients without HAQ remission (n=68), a group of patients with HAQ remission (n=164) had younger age (54.8±15.2 vs. 61.8±13.3, p=0.0011), lower baseline steroid dosage (3.4±3.7mg vs. 4.5±3.5mg, p=0.037), lower serum MMP-3 (196±234 ng/ml vs. 321±551, p=0.047), lower SDAI (22.5±13.4 vs. 32.1±12.9, p&lt;0.001), lower HAQ (0.39±0.51 vs. 1.08±0.54, p&lt;0.001), higher SF-36 (p&lt;0.05 in all categories), lower SDS (40.4±9.9 vs. 43.5±9.2, p=0.033), and lower HAM-D (5.0±4.3 vs. 8.4±5.0, p&lt;0.001). On the other hand, there was no significant difference on the types of biologic agents, the order of drugs used in the treatment, gender, MTX dosage, disease duration, serum RF, ACPA, TNF-α, and IL-6. <h3>Conclusions</h3> It was suggested that RA patients with lower disease activity, lower dosage of steroid, younger age, lower serum MMP-3, higher ADL and QOL, and lower depression scores at baseline are more likely to achieve HAQ remission with biologic treatment. <h3>Disclosure of Interest</h3> Y. Miwa Grant/research support from: Astellas Pharm Inc., Mitsubishi Tanabe Pharma Corporation, AbbVie CK, Pfizer Japan Inc., Chugai Pharmaceutical Co., Ltd., and Eizai Co., Ltd., R. Takahashi: None declared, N. Yajima: None declared, K. Wakabayashi: None declared, T. Tokunaga: None declared, S. Ishii: None declared, A. Nishimi: None declared, T. Kasama: None declared, K. Oh: None declared, Y. Toyoshima: None declared, K. Inagaki: None declared
SAT0591 Local steroid injection versus wrist splinting for carpal tunnel syndrome: a randomized clinical trial
Authors: H So, V Chung, J Cheng, ML Yip
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Carpal tunnel syndrome (CTS) can lead to significant symptoms and loss of hand function. It also has a great socio-economic impact. However, there is no consensus regarding its best treatment up to this moment. Local steroid injection and wrist splinting are among the most popular nonsurgical treatment options. Previous studies have confirmed their respective effectiveness. However, there is no high quality head to head comparative study regarding the two treatments in the literature. <h3>Objectives</h3> To compare the efficacy of local steroid injection and nocturnal wrist spiniting for CTS. <h3>Methods</h3> We conducted a prospective randomised parallel clinical trial comparing the efficacy of local steroid injection and nocturnal wrist splinting in patients with CTS. The well validated and disease specific Boston Carpal Tunnel Questionnaire (BCTQ) was employed and its score at 4 weeks after treatment was used as the primary outcome measure. Important secondary outcomes included the patient satisfaction, the change of an objective finger dexterity test 9-hole-peg test, and the side effects. <h3>Results</h3> Twenty-five patients in the local steroid group and 25 patients in the wrist splinting group completed the study procedures. The baseline patient and clinical characteristics of the two treatment groups were similar. At 4 weeks after treatment, there was significant improvement of the BTCQ scores in both the steroid group and splinting group. There was improvement of the 9-hole-peg test only in the steroid group but not in the splinting group. However, there was no statistically significant difference in the changes of BTCQ scores between the two groups after treatment. Patient satisfaction score was higher in the steroid group. Patient in the steroid group took less painkillers after treatment. Four patients developed side effects after splinting and 3 after local steroid injection, which was not statistically significant. <h3>Conclusions</h3> Although local steroid injection and nocturnal wrist splinting were equally effective in the treatment of patients with CTS, only the former improved objective hand function. Local steroid injection also resulted in better patient satisfaction and less painkiller use without causing more side effects. <h3>Disclosure of Interest</h3> None declared
AB0548 Circulating prolactin level in systemic lupus erythematosus and its correlation with disease activity: a meta-analysis
Authors: YH Lee, YH Seo
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Prolactin has an immune stimulatory effect and may promote autoimmunity by encouraging the development of antigen presenting cells expressing MHC class II and co-stimulatory molecules and modulating IFN-γ secretion. <h3>Objectives</h3> This study aimed to evaluate the relationship between circulating prolactin level and systemic lupus erythematosus (SLE), and to establish a correlation between plasma/serum prolactin levels and SLE activity. <h3>Methods</h3> We performed a literature search for studies that examined prolactin status in SLE patients and controls, and the relationship between circulating (serum or plasma) prolactin levels and SLE using PUBMED, EMBASE, and Cochrane databases. We conducted a meta-analysis comparing the plasma/serum prolactin levels in patients with SLE to controls, and examined correlation coefficients between circulating prolactin level and SLE disease activity. <h3>Results</h3> Twenty-five studies with a total of 1,056 SLE patients and 426 controls were included. Prolactin levels were significantly higher overall in the SLE group than in the control group (SMD =0.987, 95% CI =0.512 – 1.463, <i>p</i>=4.7x10<sup>-5</sup>). Stratification by ethnicity showed significantly elevated prolactin levels in the SLE group in Asian, Latin American, and mixed populations (SMD =0.813, 95% CI =0.137 – 1.490, <i>p</i> =0.018; SMD =0.981, 95% CI =0.307 – 1.655, <i>p</i> =0.004; SMD =1.469, 95% CI =0.443 – 2.495, <i>p</i> =0.005, respectively), but not in the European population. Meta-analysis of correlation coefficients showed a significantly positive correlation between circulating prolactin level and SLE activity (Correlation coefficient =0.379, 95% CI =0.026–0.487, <i>p</i>=4.0x10<sup>-9</sup>). <h3>Conclusions</h3> Our meta-analysis demonstrated that circulating prolactin levels are higher in patients with SLE and that a significantly positive correlation exists between prolactin levels and SLE activity. <h3>Acknowledgements</h3> None. <h3>Disclosure of Interest</h3> None declared
Immediate interruption of sedation compared with usual sedation care in critically ill postoperative patients (SOS-Ventilation): a randomised, parallel-group clinical trial
Authors: Gerald Chanques, Matthieu Conseil, Claire Roger, Jean-Michel Constantin, Albert Prades, Julie Carr, Laurent Muller, Boris Jung, Fouad Belafia, Moussa Cissé, Jean-Marc Delay, Audrey de Jong, Jean-Yves Lefrant, Emmanuel Futier, Grégoire Mercier, Nicolas Molinari, Samir Jaber, Gerald Chanques, Matthieu Conseil, Albert Prades, Julie Carr, Boris Jung, Fouad Belafia, Moussa Cissé, Jean-Marc Delay, Audrey De Jong, Daniel Verzilli, Noémie Clavieras, Samir Jaber, Grégoire Mercier, Nicolas Molinari, Emmanuelle Mathieu, Héléna Bertet, Claire Roger, Laurent Muller, Jean-Yves Lefrant, Caroline Boutin, Jean-Michel Constantin, Emmanuel Futier, Sophie Cayot, Sébastien Perbet, Matthieu Jabaudon
Journal: The Lancet Respiratory Medicine (2017)
Rescue antegrade diathermic dilation of hyperplastic tissue at partially covered metallic stent after EUS-guided hepaticogastrostomy
Authors: Hiroshi Kawakami, Yoshimasa Kubota, Tesshin Ban
Journal: Endoscopy (2017)

Endoscopic ultrasonography-guided antegrade stenting (EUS-AGS) and EUS-guided hepaticogastrostomy (EUS-HGS) are suitable for obstructive jaundice associated with gastric outlet obstruction or surgically altered anatomy [1]. Recently, a long partially covered self-expandable metallic stent (LPC-SEMS) has been developed to prevent stent migration and bile leakage and allow safe and effective EUS-HGS. However, one disadvantage of the LPC-SEMS is tissue hyperplasia at the uncovered portion of the stent [2]. Here, we present the case of a patient who underwent a rescue procedure using antegrade diathermic dilation for hyperplastic tissue occlusion of an LPC-SEMS and for tumor ingrowth into an uncovered SEMS placed for EUS-AGS.
FRI0416 Characteristics and capillaroscopic findings of systemic sclerosis patients with severe peripheral vascular involvement receiving specific vasodilator treatment
Authors: Y Yalçınkaya, AU Ünal, Z Ertürk, U Gazel, S Kaymaz, A Aksoy, P Atagündüz, N İnanç, H Direskeneli
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Severity of peripheral vascular involvement (PVI)is known as an important determinig cause of morbidity in sytemic sclerosis (SSc). Different vasodilating agents have been found to reduce severity and contribute to healing of digital ulcers (DU)in SSc. <h3>Objectives</h3> We aimed to evaluate the characteristics and capillaroscopic patterns of the patients with severe PVI under different vasodilator therapeutic regimens. <h3>Methods</h3> The patients were grouped as "severe PVI" if score of PVI is ≥2 (PVT=2,digital pitting scars; PVT=3, digital tip ulcerations and PVT=4, digital gangrene; Medsger) and "non-severe PVI" if score of PVI is ≤1 (PVI=0,no Raynaud9s; PVI=1, Raynaud9s requiring vasodilators). We included patients with severe PVI who received cyclic iloprost and bosentan and/or sildenafil and compared to non-severe PVI. Nail fold video-capillaroscopy (NVC)was assessed qualitatively (Cutalo et al., early, active and late patterns). <h3>Results</h3> Severe PVI group more frequently had diffuse cutaneous form, contractures, lung disease, anti-Scl70 positivity and high acute phase response and exposed to immunosuppressives (table-1). Scores of telangiectasia, skin, activity and severity were lower in non-severe group. NVC late pattern was frequent and early pattern was rare in severe PVI groups. Forty-one% (9/22) of patients received second oral agent for PVI. Monotherapy and combination groups had similar scores (table-2). <h3>Conclusions</h3> NVC late pattern was frequent in severe PVI group with long disease duration, exposed to intensive immunosuppresives and received specific vasodilators for PVI. Disease activity and severity were higher in severe PVI group. One third of the severe group required oral combination therapy for PVI. Monotherapy and combination groups were similar in terms of severity. NVC is a useful method to monitor digital ischemia and severe organ involvement in SSc. <h3>Disclosure of Interest</h3> None declared
AB0531 Anti-centromere positive primary sjÖgren's syndrome – challenge to classification criteria
Authors: S Palshina, V Vasiliev, E Sokol, B Chaltsev, E Rodionova, T Safonova
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> The prevalence of anti-centromere antibodies (ACA) among patients with primary Sjögren9s syndrome (pSS) varies from 3,7% till 10,9% [1;2]. They have special course of the disease: 1) with some features of systemic sclerosis (SSc), but rarely evolve to it, 2) higher prevalence of hepatitis and primary biliary cholangitis - PBC. <h3>Objectives</h3> to describe the peculiarities of this subgroup; to evaluate it9s conformity to the latest classification criteria for pSS (2012, 2016) [3;4] and prevalence of SSc with ACR2013 criteria [5]. <h3>Methods</h3> From 2012 to 2016 in a single rheumatic center 50 ACA positive patients (47 female; 3 male) national (Russian) criteria (1987) and in 68%cases - AECG 2002 criteria for pSS (SSc excluded) [Tabl.1]. The mean age was 59,2±9,6 yrs. All diagnostics methods are listed in the table 1, lymphomas were verified pathomorphologicaly with immunohystochemical staining. <h3>Results</h3> In our study 2/3 (64%) ACA+pts with pSS did9t fulfill ACR2012 criteria, because of the lack of aRo or aLa or combination of RF+ANA. According to the criteria, 2016 [4] also just 60–68% pts will have ≥4scores for diagnosing pSS. SSc (limited form) due to new criteria [5] might be revealed in 11/50 (22%) cases. MALT lymphoma of salivary glands arised in 5/6 pts with visible enlargement of parotid glands. <h3>Conclusions</h3> pSS with positive ACA is challenging for diagnostics with comprehensive classification criteria (32–64% doesn9t meet it [3;4]). These patients overlaps SSc, some PBC. PBC is not rare among, but biliary tract lesions (AMA+(rarely absent, 2% in our study) with slightly elevated liver enzymes, esp.GGT, and stage 1 typical to PBC without progression) are more common. <h3>References</h3> Bournia VK et al. Anticentromere antibody positive Sjögren9s Syndrome: a retrospective descriptive analysis. Arthritis Res Ther. 2010;12(2): R47. Nakamura H et al. Anti-centromere antibody-seropositive Sjögren9s syndrome differs from conventional subgroup in clinical and pathological study. BMC Musculoskelet Disord. 2010 Jul 1;11:140. Shiboski SC et al. American College of Rheumatology Classification Criteria for Sjögren9s Syndrome: A Data-Driven, Expert Consensus Approach in the SICCA Cohort. Arthritis Care Res (Hoboken). 2012; 64(4): 475–487. Shiboski SC et al. 2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren9s Syndrome. ARTHRITIS &amp; RHEUMATOLOGY. 2016; Vol. 00 (00): p 00–00. van den Hoogen F et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013 Nov;65(11):2737–47. <h3>Disclosure of Interest</h3> None declared
OP0171 Signal intensity alteration within infrapatellar fat pad predicts total knee arthroplasty within four years: data from the osteoarthritis initiative
Authors: K Wang, C Ding, MJ Hannon, Z Chen, C Kwoh, DJ Hunter
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Osteoarthritis (OA) is a common joint disease that frequently affects the knee and is the leading cause of total knee arthroplasty (TKA) in Western countries. The most common reason for TKA is to ease pain and disability. Investigation on prognostic factors associated with TKA could be a possible way to find therapeutic targets to slow disease progression and delay the time for knee replacement. <h3>Objectives</h3> To investigate whether infrapatellar fat pad (IPFP) signal intensity (SI) alteration predicts the occurrence of TKA in patients with knee OA over 4 years. <h3>Methods</h3> Participants with symptomatic knee OA were selected from the Osteoarthritis Initiative (OAI) study. Case knees (n=127) were defined as those that received TKA during 4 years follow-up visit. They were matched by gender, age and radiographic status measured at baseline with a control knee. We used T2 weighted MR images to measure IPFP SI alteration using a newly developed algorithm in MATLAB. The measurements were assessed at OAI baseline (BL), T0 (the visit when TKA was reported), 1 year prior to T0 (T1). Conditional logistic regression was used to assess the relationship between cases and control knees and assess the risk of TKA in regard to SI alteration. <h3>Results</h3> Participants (n=237) were mostly female (57%), with average age of 63.7±8.5 years old and mean BMI of 29.5±4.7 kg/m<sup>2</sup>. In multivariable analysis, standard deviation of IPFP SI [sDev (IPFP)] and the ratio of high SI region volume to whole IPFP volume [Percentage (H)] measured at BL were significantly associated with TKA after adjustment for BMI, knee bending activities, self-reported knee injury and surgery history (HR: 3.5, 95% CI 1.1 to 11.4; HR: 8.9, 95% CI 1.2 to 67.2). IPFP SI alterations measured at T1 including sDev (IPFP), Percentage (H) and clustering effect of high SI [Clustering factor (H)] were significantly associated with TKA (HR: 4.0, 95% CI 1.2 to 13.2; HR 10.9, 95% CI 1.9, 63.6; HR: 1.8, 95% CI 1.1 to 2.9). All measurements including mean value of IPFP SI [Mean (IPFP)], sDev (IPFP), mean value of IPFP high SI [Mean (H)], standard deviation of IPFP high SI [sDev (H)], median value of IPFP high SI [Median (H)], upper quartile value of IPFP high SI [UQ (H)], Percentage (H), Clustering factor (H) were significantly associated with TKA at T0. <h3>Conclusions</h3> IPFP SI is an important predictor for TKA in knee OA patients. Targeting IPFP SI could be a potential way to reduce the need for future TKA. <h3>Acknowledgements</h3> Special thanks go to the participants who made this study possible, the OAI investigators, staff, participants and the funding of POMA study. <h3>Disclosure of Interest</h3> None declared
Current practice of allergy diagnosis and the potential impact of regulation in Europe
Authors: V. Cardona, P. Demoly, S. Dreborg, A. F. Kalpaklioglu, L. Klimek, A. Muraro, O. Pfaar, T. A. Popov, H. J. Hoffmann
Journal: Allergy (2017)

In the European Union (EU), the regulatory framework regarding diagnostic allergen extracts is currently in the process of being implemented at the national level. Due to these regulations, the initial and periodic renewal expenses for the registration of diagnostic allergen extracts may render extract production unprofitable. Consequently, many extracts may be at risk of removal from the market. The current survey, which was conducted by a task force of the European Academy of Allergy and Clinical Immunology, aimed to assess the current practice of allergy diagnosis in Europe. This survey revealed that skin tests continue to be the main diagnostic procedure and are used as the first option in almost two-third of all types of allergic diseases and in 90% of individuals suffering from respiratory allergies. Therefore, there is a need to ensure the availability of high-quality allergen extracts to maintain the common diagnostic procedures used by EU professionals. To reach this goal, it is necessary to align efforts and establish active partnerships between manufacturers, relevant scientific societies, consumer organizations and authorities to maintain the availability of these diagnostic tools.
フェニルテルピリジン誘導体標的細胞膜とトリガ死とルテニウム錯体は腫瘍細胞においてアポトーシスを受容体仲介【Powered by NICT】
Authors: Deng Zhiqin, Gao Pan, Yu Lianling, Ma Bin, You Yuanyuan, Chan Leung, Mei Chaoming, Chen Tianfeng
Journal: Biomaterials (2017)